FMP
Shattuck Labs, Inc.
STTK
NASDAQ
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
1.15 USD
0.11 (9.57%)
We are unable to load the chart at this time.
Dr. Taylor H. Schreiber M.D., Ph.D.
Healthcare
Biotechnology
NASDAQ
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
0001680367
US82024L1035
82024L103
500 West 5th Street
512 900 4690
US
75
Oct 9, 2020
We are unable to load the chart at this time.
We are unable to load the chart at this time.
0001680367
NASDAQ
Biotechnology
Healthcare
82024L103
US82024L1035
US
1.15
1.86
666.84k
54.9M
-
0.94-11.76
1.61
-
-
-
-
-0.75
-
https://www.shattucklabs.com
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.